Edge
Edge, licence 80116551: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Plexus Edge
- Licence holder
- Plexus Canada Limited Partnership dba Plexus Worldwide
- NPN or DIN-HM
- 80116551
- Status
- Inactive licence
- Licence date
- 18 February 2022
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 1,3,7-triméthylxanthine Source : Coffea canephora - Graine | 90.0 mg | Not calculated |
| 1,3,7-triméthylxanthine Source : Caféine | 90.0 mg | Not calculated |
| 7,9-Dihydro-1,3,7,9-tétraméthyl-1H-purine-2,6,8(3H)-trione Source : Théacrine | 125.0 mg | Not calculated |
| L-théanine Source : L-Théanine | 100.0 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Stéarate de magnésium, Cellulose microcristalline, Silicate de calcium, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 Année(s) | 1.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to temporarily increase energy and to reduce fatigue. Helps support cognitive performance. Helps to temporarily improve sustained attention. Helps to temporarily improve sustained attention in 60 minutes. Helps to temporarily support sustained attention. Helps to temporarily improve mental alertness. Helps to temporarily promote mental focus.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80116551
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.